Mpox
ICD-10 B04 · ICD-11 1E71

Mpox Treatment in Pregnant or Breastfeeding Patients

Treating Mpox in patients who are pregnant or breastfeeding requires a specific clinical approach. The safety of standard antiviral options has not been established in this population, which directs management toward an alternative protocol.

Clinical Scenario
Pregnancy Breastfeeding

This protocol applies to patients with Mpox who are currently pregnant or breastfeeding. Because the safety of certain antiviral therapies has not been established in these patients, a distinct treatment pathway is indicated.

Treatment Approach

Management in this setting involves an intravenously administered vaccinia immune globulin (VIG) preparation. Depending on the patient's clinical response, repeated treatment courses may be necessary.

Complete dosing, infusion parameters, and escalation criteria are detailed in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

  1. It may need to be used when the safety of Tecovirimat has not been established such as during pregnancy and breastfeeding.
  2. Persons who are pregnant or breastfeeding (see VIG under Treatment Options).
  3. VIG is held in the NMS in limited quantities. It may need to be used when the safety of Tecovirimat has not been established such as during pregnancy and breastfeeding.
  4. Dose of 6000 Units/kg intravenous.
  5. Consider higher doses where the patient does not respond to the initial dose. Multiple and repeated treatments may be required.
  6. Bring VIG vials to room temperature prior to dosing. Administer 6000 U/kg intravenously through a dedicated intravenous line with the infusion rate of no greater than 2 mL/min.
View source ↗